Austar Lifesciences Limited (HKG:6118)
Hong Kong · Delayed Price · Currency is HKD 0.8100
0.00 (0.00%)
Feb 11, 2026, 4:08 PM HKT
Austar Lifesciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,461 | 1,500 | 1,764 | 2,157 | 2,015 | 1,296 | |
Revenue Growth (YoY) | -5.42% | -14.93% | -18.23% | 7.04% | 55.48% | 23.54% |
Cost of Revenue | 1,166 | 1,199 | 1,428 | 1,668 | 1,536 | 972.45 |
Gross Profit | 294.94 | 301.22 | 336.05 | 488.8 | 479.01 | 323.53 |
Selling, General & Admin | 238.05 | 239.08 | 300.99 | 305.93 | 298.38 | 247.39 |
Research & Development | 46.56 | 53.55 | 55.33 | 70.16 | 65.6 | 48.27 |
Other Operating Expenses | -24.04 | -25.97 | -11.15 | -6.94 | -7.63 | -10.44 |
Operating Expenses | 259.34 | 266.45 | 377.26 | 366.01 | 362.04 | 297.15 |
Operating Income | 35.6 | 34.77 | -41.21 | 122.79 | 116.97 | 26.38 |
Interest Expense | -14.46 | -17.01 | -13.96 | -9.59 | -4.4 | -2.79 |
Interest & Investment Income | 2.19 | 2.9 | 3.29 | 2.27 | 1.47 | 3.12 |
Earnings From Equity Investments | 2.07 | 0.3 | 6.73 | 9.54 | 10.66 | 10.48 |
Currency Exchange Gain (Loss) | 9.88 | -4.1 | 6.83 | -5.17 | -3.74 | 4.36 |
Other Non Operating Income (Expenses) | -0.19 | -0.19 | -0.19 | - | - | - |
EBT Excluding Unusual Items | 35.09 | 16.67 | -38.51 | 119.83 | 120.95 | 41.54 |
Gain (Loss) on Sale of Investments | -0.42 | -0.42 | - | - | 198.99 | - |
Gain (Loss) on Sale of Assets | -0.58 | -0.2 | 4.1 | -0.3 | -0.72 | -0.05 |
Other Unusual Items | 8.2 | 5.13 | - | - | - | - |
Pretax Income | 42.29 | 21.17 | -34.41 | 119.53 | 319.23 | 41.49 |
Income Tax Expense | 9.29 | 7.6 | 0.38 | 18.89 | 46.6 | 9.88 |
Earnings From Continuing Operations | 33 | 13.57 | -34.79 | 100.64 | 272.62 | 31.61 |
Earnings From Discontinued Operations | - | - | -80.87 | -16.78 | - | - |
Net Income to Company | 33 | 13.57 | -115.66 | 83.86 | 272.62 | 31.61 |
Minority Interest in Earnings | 2.2 | 2.51 | 2.18 | 3.6 | 4.68 | 1.5 |
Net Income | 35.2 | 16.08 | -113.47 | 87.46 | 277.3 | 33.1 |
Net Income to Common | 35.2 | 16.08 | -113.47 | 87.46 | 277.3 | 33.1 |
Net Income Growth | - | - | - | -68.46% | 737.76% | 309.10% |
Shares Outstanding (Basic) | 513 | 513 | 513 | 513 | 513 | 513 |
Shares Outstanding (Diluted) | 513 | 513 | 513 | 513 | 513 | 513 |
EPS (Basic) | 0.07 | 0.03 | -0.22 | 0.17 | 0.54 | 0.06 |
EPS (Diluted) | 0.07 | 0.03 | -0.22 | 0.17 | 0.54 | 0.06 |
EPS Growth | - | - | - | -68.40% | 800.00% | 280.13% |
Free Cash Flow | 92.04 | 78.31 | -131.88 | -155.04 | -204.02 | 25.68 |
Free Cash Flow Per Share | 0.18 | 0.15 | -0.26 | -0.30 | -0.40 | 0.05 |
Gross Margin | 20.18% | 20.08% | 19.05% | 22.66% | 23.77% | 24.96% |
Operating Margin | 2.44% | 2.32% | -2.34% | 5.69% | 5.80% | 2.04% |
Profit Margin | 2.41% | 1.07% | -6.43% | 4.06% | 13.76% | 2.55% |
Free Cash Flow Margin | 6.30% | 5.22% | -7.48% | -7.19% | -10.13% | 1.98% |
EBITDA | 66.64 | 65.07 | -19.82 | 137.06 | 130.62 | 39.83 |
EBITDA Margin | 4.56% | 4.34% | -1.12% | 6.35% | 6.48% | 3.07% |
D&A For EBITDA | 31.04 | 30.29 | 21.4 | 14.27 | 13.65 | 13.45 |
EBIT | 35.6 | 34.77 | -41.21 | 122.79 | 116.97 | 26.38 |
EBIT Margin | 2.44% | 2.32% | -2.34% | 5.69% | 5.80% | 2.04% |
Effective Tax Rate | 21.97% | 35.90% | - | 15.81% | 14.60% | 23.82% |
Advertising Expenses | - | 6.55 | 8.6 | 5.83 | 12.76 | 12.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.